UT Southwestern Medical Center has received exemplar status by the Nurses Improving Care for Healthsystem Elders (NICHE).

Summertime means lots of opportunities for fun in the sun. But this year’s high temperatures also bring an increased risk of dehydration that can cause urinary tract infections (UTIs), said Maude Carmel, M.D., Associate Professor of Urology at UT Southwestern Medical Center.

Vaginal progesterone, a hormone treatment considered the standard of care for preventing preterm birth in at-risk pregnant women, may not be effective, according to UT Southwestern researchers.

The use of abdominal ice packs is a safe and effective way to help manage postoperative pain for patients who have had laparoscopic hysterectomies, an investigation by UT Southwestern clinicians has found.

Women with chronic hypertension and diabetes who were enrolled in an award-winning program for 12 months after childbirth were more likely to keep follow-up health care visits, which in turn led to improved care, according to initial findings of the program published in The Joint Commission Journal

A team at UT Southwestern has developed a computational approach to uncover mechanisms of protein misfolding linked to neurodegenerative diseases. The study, published in Nature Communications, offers key insights that could help identify new treatments for patients.

For three decades, scientists have debated the underlying cause of Gulf War illness (GWI), a collection of unexplained and chronic symptoms affecting veterans of the Persian Gulf War.

UT Southwestern is ranked among the top 20 medical schools for primary care and the top 25 for research in the United States, according to U.S. News & World Report’s 2023 Best Graduate Schools rankings.

A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill clinical trials and enroll sufficiently diverse groups of patients for results to reflect the broader population, in part because of stringent guidelines on who can participate.

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non-small cell lung cancers (NSCLCs) to respond to an immune checkpoint blockade (ICB), a therapy that harnesses the immune system to fight malignant tumors.